Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 2: NASH and NAFLD: Emerging drugs, therapeutic targets and translational and clinical challenges
Submit an article Journal homepage
6,899
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)

Naim AlkhouriTexas Liver Institute, University of Texas Health San Antonio (UTHSA), San Antonio, TX, USACorrespondence[email protected]
View further author information
Pages 99-101 | Received 05 Dec 2019, Accepted 20 Dec 2019, Published online: 25 Dec 2019

References

  • Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–315. PubMed PMID: 27322798.
  • Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685. PubMed PMID: 20427778.
  • Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–357. PubMed PMID: 28714183. Epub 2017/ 07/18.
  • Bohinc BN, Michelotti G, Xie G, et al. Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. Endocrinology. 2014;155(11):4591–4601. Epub 2014/08/15. PubMed PMID: 25121996; PubMed Central PMCID: PMCPMC4256825.
  • Krause C, Grohs M, El Gammal AT, et al. Reduced expression of thyroid hormone receptor beta in human nonalcoholic steatohepatitis. Endocr Connect. 2018;7(12):1448–1456. Epub 2018/11/30. PubMed PMID: 30496129; PubMed Central PMCID: PMCPMC6300861.
  • Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(2):528–534. PubMed PMID: 22183820; PubMed Central PMCID: PMCPMC3922233. Epub 2011/ 12/21
  • Kim D, Kim W, Joo SK, et al. Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol. 2018;16(1):123–31 e1. Epub 2017/ 08/22. PubMed PMID: 28823829.
  • Sinha RA, Yen PM. Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD. Cell Biosci. 2016;6:46. Epub 2016/07/21. PubMed PMID: 27437098; PubMed Central PMCID: PMCPMC4950712.
  • Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A. 2005;102(29):10297–10302. Epub 2005/07/12. PubMed PMID: 16006512; PubMed Central PMCID: PMCPMC1177400.
  • Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–735. Epub 2013/ 12/10. PubMed PMID: 24316260; PubMed Central PMCID: PMC6276362.
  • Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009;8(4):308–320. Epub 2009/ 04/02. PubMed PMID: 19337272.
  • Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dio xo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor beta agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014;57(10):3912–3923. Epub 2014/ 04/10. PubMed PMID: 24712661.
  • Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019:394:2012–2024. Epub 2019/11/16. PubMed PMID: 31727409.
  • Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–121. Epub 2005/ 07/14.PubMed PMID: 16012941.
  • Alkhouri N, Lawitz E, Noureddin M, et al. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2019;1–7. Epub 2019/09/15. PubMed PMID: 31519114. DOI:10.1080/13543784.2020.1668374

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.